Pascua PNQ, Jones JC, Marathe BM, Seiler P, Caufie. Baloxavir treatment delays influenza B virus transmission in ferrets and results in limited generation of drug-resistant variants. Antimicrob Agents Chemother. 2021 Aug 23:AAC011372
Clinical efficacy of the influenza antiviral baloxavir marboxil (baloxavir) is compromised by treatment-emergent variants harboring a polymerase acidic protein I38T substitution. However, the fitness of I38T-containing influenza B viruses (IBVs) remains inadequately defined. After confirming the pharmacokinetics of the compound in ferrets, animals were injected subcutaneously with 8 mg/kg of baloxavir acid (BXA) 24 h post-inoculation with recombinant BXA-sensitive (BXA-Sen, I38) or BXA-resistant (BXA-Res, I38T) B/Brisbane/60/2008 (Victoria lineage) virus. BXA treatment of donor ferrets reduced virus replication and delayed transmission of the BXA-Sen but not the BXA-Res IBV. The I38 genotype remained dominant in the BXA-Sen animals, even under BXA treatment. In competitive-mixture experiments, no transmission to aerosol-contacts was seen from BXA-treated donors coinfected with the BXA-Sen and BXA-Res B/Brisbane/60/2008 viruses. However, in parallel mixed-infections with the B/Phuket/3073/2013 (Yamagata lineage) virus background, BXA treatment failed to block airborne transmission of the BXA-Res virus and the I38T genotype generally predominated. Therefore, relative fitness of BXA-Res IBVs is complex and dependent on the virus backbone and within-host virus competition. BXA treatment of single-virus infected ferrets hampers aerosol transmission of the BXA-Sen virus and does not readily generate BXA-Res variants, while mixed-infections may result in propagation of BXA-Res IBVs of the Yamagata lineage. Our findings confirm the antiviral potency of baloxavir against IBVs while supporting optimization of the dosing regimen to maximize clinical benefit.
Latest articles in those days:
[Go Top] [Close Window]